Pfizer Looks To Aquire Foldrx, Stock Updates On Abt And Nwtt From Pennytobuck.com

NW Tech Capital Inc., (PINK SHEETS:NWTT) recently reported that the company is currently

working on raising the company value back for its shareholders and seeks viable candidates to merge into NWTT. The company management has been seeking viable businesses to vend in in North America, Asia, and Europe. NWTT is determined to reenter the public markets as a viable and respectable business.

NWTT also recently reported that the company had finalized the merger with Bermal Contracting Ltd., a BC Canada company.

NWTT management currently works on raising the company value back for its shareholders and seeks viable candidates to merge into NWTT. NWTTs management has been seeking viable businesses to vend in, in North America, Asia and Europe. NWTT is determined to reenter the public markets as a viable and respectable business.

To receive additional information about NWTT, please visit the website at http://www.nwtechcapital.com

Abbott Laboratories, (NYSE:ABT)

Imagine needing a critical test at your local hospital, but having to wait days to be tested because there was no laboratory professional available to run the tests. This scene seems unimaginable, but its a reality in some parts of the United States, such as California.

The Abbott Fund is helping reverse this trend by supporting Californias Healthcare Laboratory Workforce Initiative (HLWI), which has helped to more than double the number of hospitals that provide on-site clinical training for aspiring laboratory science workers.

The boost in Californias lab workforce is helping to ease a serious staffing crisis. The closing of training programs at universities and hospitals, as well as aging lab technologists without an ample supply of successors, led to an average shortage of four full-time employees per hospital laboratory in the state. By helping to establish new training sites, HLWI is motivating hospitals to develop and retain their own staff. Offering training opportunities with pathways toward full-time employment lowers recruitment costs and shortens the learning curve for new workers.

To receive additional information about ABT, please visit the website at http://www.abbott.com/

Pfizer Inc. (NYSE:PFE) and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, recently announced that they have entered into an agreement under which PFE will acquire FoldRx.

FoldRx's portfolio includes clinical and pre-clinical programs for investigational compounds to treat diseases caused by protein misfolding, which is increasingly recognized as an underlying cause in many chronic degenerative diseases. FoldRx's lead product candidate, tafamidis meglumine, is in registration as an oral, disease-modifying therapy for TTR amyloid polyneuropathy , a progressively fatal genetic neurodegenerative disease, for which liver transplant is the only treatment option that is currently available.

About Transthyretin Amyloidosis (ATTR-PN)

Transthyretin (TTR) is an amyloidogenic protein secreted by the liver. Mutations in the TTR gene have been linked to several amyloid conditions. Deposition of TTR amyloid in the peripheral nerve tissue results in transthyretin amyloid polyneuropathy (ATTR-PN), a sensory, motor and autonomic polyneuropathy. The disease usually begins in the third or fourth decade with symptoms of peripheral and/or autonomic neuropathy that inexorably progress to involve muscle strength with loss of ambulation. The patient commonly experiences a profoundly diminished quality of life with a markedly reduced life expectancy (approximately 10 years from first symptom). Liver transplantation is the only accepted treatment, but it is not uniformly effective, and is associated with significant mortality. It is estimated that ATTR-PN affects at least 8,000 patients worldwide, the majority of whom are in the European Union.

About FoldRx

FoldRx is a development and discovery company focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding and aggregation (amyloidosis) based on the pioneer work of its scientific founders, Jeffery Kelly (The Scripps Research Institute) and Susan Lindquist (Whitehead Institute). Protein misfolding is increasingly being recognized as an underlying cause of many chronic degenerative diseases. By applying FoldRx's proprietary expertise in protein folding and its platform for drug and target discovery, the company is building a pipeline, initially for neurodegenerative and respiratory conditions. FoldRx's pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, Transthyretin (TTR) Amyloid Polyneuropathy (ATTR-PN) and TTR Amyloid Cardiomyopathy (ATTR-CM), and a discovery program in cystic fibrosis, Parkinson's, and Huntington's disease based on its broad, proprietary, yeast-based drug discovery platform. FoldRx investors include Alta Partners, Fidelity Biosciences, Healthcare Ventures, Morgenthaler Ventures, Novartis Venture Funds, Novo Ventures, and TPG Biotechnology. For more information on FoldRx, please visit the company's web site at www.foldrx.com.

For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received fifteen thousand dollars in cash from a third party (PenStox) for (15) days of advertising for NW Tech Capital, Inc. (NWTT.PK).

by: Bill Pennyman

POST COMMENT

Adams Golf (NASDAQ:ADGF): Ryder Cup Stocks The Hidden Ramon Desage And His Good Deeds The Who Dat Nation Camps Out Under The Who Dat Tent And Wait For Brett Favre Life, Hlf And Prot Stock Updates From Pennytobuck.com Out And About In North Norfolk How Tool Makers And Die Makers Overlap And The Differences Between Tool Makers And Jig Makers The Benefits To Driving Scooters And Mopeds Walgreens And Cvs Top 5 3D Animated Films And Characters Of All Time Choice Considerations for stocks to boost your results on investment Is Every Day A Race Between You And A Clock? Good Swing Trading Stocks - Swing Trading As a Source of Income Heme, Ccoi And Crwe Stock Updates From Pennytobuck.com